Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The company’s earnings surpassed estimates in each of the trailing four ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

FRANKFURT, Jan 31 (Reuters) - Novartis (NOVN.S), opens new tab on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer ...

Novartis (NVS) reported $13.15 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 15.1%. EPS of $1.98 for the same period compares to $1.53 a year ago.

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings (excluding one-time charges) of $1.98 per share easily beat the Zacks ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company ...

The transaction is expected to close in the first half of 2025. Also Read: Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries The transaction aligns with ...

Novartis shares jumped 3.6% to a three-month high of 97.15 francs at 0941 GMT, with investors also encouraged by the company's upbeat 2025 earnings projections. News Today's news ...